PD-1 inhibition in metastatic dMMR/MSI-H colorectal cancer

被引：42
|
作者：
Sclafani, Francesco [1 ]
机构：
[1] Royal Marsden NHS Fdn Trust, Sutton SM2 5PT, Surrey, England
来源：
LANCET ONCOLOGY | 2017年 / 18卷 / 09期
关键词：
D O I：
10.1016/S1470-2045(17)30512-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1141 / 1142
页数：3
相关论文
共 50 条
  • [21] KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer
    Andre, Thierry
    Pietrantonio, Filippo
    Avallone, Antonio
    Gumus, Mahmut
    Wyrwicz, Lucjan
    Kim, Jong Gwang
    Yalcin, Suayib
    Kwiatkowski, Mariusz
    Lonardi, Sara
    Zolnierek, Jakub
    Odeleye-Ajakaye, Amos
    Leconte, Pierre
    Fogelman, David
    Kim, Tae Won
    [J]. FUTURE ONCOLOGY, 2023, 19 (37) : 2445 - 2452
  • [22] Molecular Subtyping of dMMR/MSI-H Tumors
    Sorscher, Steven
    [J]. JCO PRECISION ONCOLOGY, 2017, 1
  • [23] Good Tumor Response to Chemoradioimmunotherapy in dMMR/MSI-H Advanced Colorectal Cancer: A Case Series
    Zhou, Chengjing
    Jiang, Ting
    Xiao, Yajie
    Wang, Qiaoxuan
    Zeng, Zhifan
    Cai, Peiqiang
    Zhao, Yongtian
    Zhao, Zhikun
    Wu, Dongfang
    Lin, Hanqing
    Sun, Chao
    Zhang, Rong
    Xiao, Weiwei
    Gao, Yuanhong
    [J]. FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [24] Pembrolizumab vs chemotherapy in MSI-H/dMMR metastatic colorectal cancer: KEYNOTE-177 final analysis Asia subgroup
    Yoshino, Takayuki
    Andre, Thierry
    Shiu, Kai-Keen
    Kim, Tae Won
    Jensen, Benny Vittrup
    Jensen, Lars Henrik
    Punt, Cornelius J. A.
    Smith, Denis
    Garcia-Carbonero, Rocio
    Gibbs, Peter
    Le Dung, T.
    Adachi, Noriaki
    Fogelman, David
    Marinello, Patricia
    Diaz, Luis A., Jr.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S471 - S471
  • [25] The clinical and genomic characteristics of MSI-h/dMMR lung cancer.
    Qin, Jianwen
    Shi, Dongsheng
    Yin, Yan
    Bin Liu
    Wang, Lei
    Sun, Tingting
    Zhang, Qin
    Qi, Chuang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] MSI-H/dMMR and cancer immunotherapy: current state and future implications
    Rizzo, Alessandro
    Ricci, Angela Dalia
    Gadaleta-Caldarola, Gennaro
    [J]. EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (06): : 345 - 347
  • [27] Real-world experience of immune checkpoint inhibitors in MSI-H/dMMR metastatic colorectal cancer in a tertiary cancer center in Saudi Arabia
    Ajina, R.
    Alhareeri, A.
    Philip, W.
    Alsekait, N.
    Alarifi, N.
    Alismail, H.
    Alshieban, S.
    Almuzzaini, B.
    Alshammari, K.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S117 - S117
  • [28] Lower tumor mutational burden (TMB) and hepatic metastases may predict for lack of response to PD-1 blockade in MSI-H metastatic colorectal cancer (MCRC)
    Amanam, I.
    Chao, J.
    Lim, D.
    Rahmanuddin, S.
    Schrock, A. B.
    Ali, S. M.
    Lau, C.
    Chevalier, D.
    Harris, E.
    Saluja, J.
    Wang, C.
    Fakih, M.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [29] Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities
    Zhang, Xuan
    Wu, Tao
    Cai, Xinyi
    Dong, Jianhua
    Xia, Cuifeng
    Zhou, Yongchun
    Ding, Rong
    Yang, Renfang
    Tan, Jing
    Zhang, Lijuan
    Zhang, Ya
    Wang, Yuqin
    Dong, Chao
    Li, Yunfeng
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [30] Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer
    Nasca, Vincenzo
    Barretta, Francesco
    Corti, Francesca
    Lonardi, Sara
    Niger, Monica
    Elez, Maria Elena
    Fakih, Marwan
    Jayachandran, Priya
    Shah, Aakash Tushar
    Salati, Massimiliano
    Fenocchio, Elisabetta
    Salvatore, Lisa
    Cremolini, Chiara
    Ros, Javier
    Ambrosini, Margherita
    Mazzoli, Giacomo
    Intini, Rossana
    Overman, Michael J.
    Miceli, Rosalba
    Pietrantonio, Filippo
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (02)
12345